Faculty, Staff and Student Publications
Publication Date
9-1-2023
Journal
Cancer Prevention Research
DOI
10.1158/1940-6207.CAPR-22-0478
PMID
37001882
PMCID
PMC10548442
PubMedCentral® Posted Date
9-1-2024
PubMedCentral® Full Text Version
Author MSS
Abstract
Cancer immunoprevention applies immunologic approaches such as vaccines to prevent, rather than to treat or cure, cancer. Despite limited success in the treatment of advanced disease, the development of cancer vaccines to intercept premalignant states is a promising area of current research. These efforts are supported by the rationale that vaccination in the premalignant setting is less susceptible to mechanisms of immune evasion compared with established cancer. Prophylactic vaccines have already been developed for a minority of cancers mediated by oncogenic viruses (e.g., hepatitis B and human papillomavirus). Extending the use of preventive vaccines to non-virally driven malignancies remains an unmet need to address the rising global burden of cancer. This review provides a broad overview of clinical trials in cancer immunoprevention with an emphasis on emerging vaccine targets and delivery platforms, translational challenges, and future directions.
Keywords
Humans, Cancer Vaccines, Antigens, Neoplasm, Immunotherapy, Precancerous Conditions, Vaccination, Papillomavirus Vaccines
Published Open-Access
yes
Recommended Citation
Haldar, Saurav D; Vilar, Eduardo; Maitra, Anirban; et al., "Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention" (2023). Faculty, Staff and Student Publications. 5079.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5079
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons